Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock wasn't much affected by the news of some rare cases of a neurological disorder after the vaccine, but shares are down after a sunscreen recall.

Johnson & Johnson Is Recalling Sunscreen. Now the Stock Is Down.

Johnson & Johnson is recalling five of its six spray sunscreens after discovering small amounts of benzene in Neutrogena and Aveeno products.

J&J recalls spray sunscreens after testing found traces of cancer-causing chemical

J&J (JNJ) withdraws five aerosol sunscreen products from the market due to "low levels" of benzene found in some samples.

J&J (JNJ) Recalls Some Sunscreens Due to Benzene Presence

Johnson & Johnson is a cash flow machine that is both a consumer product company and a pharma play. While JNJ stock is cheaper than the market as a whole, the company faces long-range risks from asbestos and opioid litigation, and from efforts to rein in healthcare costs.

Where Will Johnson & Johnson Stock Be In 5 Years?

Johnson & Johnson is recalling five of its Neutrogena and Aveeno spray sunscreens after the company found low levels of benzene, a cancer-causing chemical, in some samples.

J&J recalls Aveeno, Neutrogena sunscreens over cancer-causing chemical

Get rid of these five aerosol sunscreen products right now. Users of certain Neutrogena and Aveeno-brand sunscreens should stop using the products right away.

Neutrogena and Aveeno recall: Johnson & Johnson pulls spray sunscreens over cancer fears

Johnson & Johnson (NYSE: JNJ) said Wednesday that it is recalling five of its sunscreen products after some samples were found to contain low levels of benzene, a chemical that can cause cancer with repeated exposure. The company said that consumers should stop using the products and discard them appropriately.

Johnson & Johnson Recalls Aveeno, Neutrogena Spray Sunscreens After Finding Benzene Traces

Johnson & Johnson is issuing a voluntary recall for five Neutrogena and Aveeno sunscreen lines in the United States after it said it discovered low levels of benzene in the products.

Johnson and Johnson recalls some Neutrogena and Aveeno sunscreens after it detects benzene in them

NEW BRUNSWICK, N.J., July 14, 2021 /PRNewswire/ -- Johnson & Johnson Consumer Inc. (JJCI) (NYSE: JNJ) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines to the consumer level.

Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene

Apple

Abbott Labs

Blackrock Inc

Carrier Global

Colgate-Palmolive

CVS Health

iShares Core S&P 500 ETF

Lowe's

Medtronic

Microsoft

NIKE

Otis Worldwide

PepsiCo

QUALCOMM

Raytheon Technologies

Texas Instruments

Vanguard Dividend Appreciation ETF

Vanguard Short-Term Inflation-Protected Securities ETF

Walgreens

Walmart

U.S. stocks moved to new all-time highs in the first half of 2021 as we eye the other side of the pandemic.

Our U.S. Stock Portfolio, First Half Of 2021 Review

Dollar General

Home Depot

Olin

Twilio

Essential Utilities

With legendary investor Warren Buffett sounding worried about the pandemic, here are the stocks to buy to prepare yourself. The post 7 Stocks to Buy if You're Worried About the Pandemic Like Warren Buffett appeared first on InvestorPlace.

7 Stocks to Buy if You're Worried About the Pandemic Like Warren Buffett

American Airlines

Hewlett Packard

Mastercard

The9 Ltd. Sponsored

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Johnson & Johnson among others.

Johnson & Johnson Ranked Among Today's Trending Stocks

FDA warns of increased risk of Guillain-Barre syndrome, a rare neurological disorder with J&J's (JNJ) COVID-19 vaccine.

J&J (JNJ) COVID-19 Jab Linked to New Rare Neurological Disorder

SPDR Dow Jones Industrial Average ETF

Dow Inc

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

UnitedHealth Group

With some blue-chip companies' earnings scheduled for the coming days, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from a surge in any of the 30 stocks.

Dow ETF Set to Rise Further as Q2 Earnings Kick Off

AstraZeneca

The blood clotting, which some scientists are now calling vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been linked to both shots.

J&J, AstraZeneca explore modifying Covid vaccines in response to rare blood clot issue, report says

Moderna

Pfizer

"The data are about as good as it gets," Dr. Anthony Fauci told CNBC, saying he expects Pfizer, Moderna and J&J's vaccines to receive full FDA approval.

Fauci says he would be 'astounded' if Pfizer, Moderna and J&J Covid vaccines don't get full FDA approval

Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine has been linked to a second rare but severe side effect. The FDA issued a warning that there are data "connecting the shot to an increased risk" of Guillain-Barré syndrome, a rare condition where the body's immune system attacks its nerves.

FDA Adds Rare Nerve Condition As Second Warning To Johnson & Johnson's COVID-19 Vaccine

Things are finally looking up for the healthcare giant's COVID-19 vaccine.

How Johnson & Johnson's COVID Vaccine Is Making a Comeback

BioNTech SE

Novavax

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

News for Johnson & Johnson Stock (JNJ)